NUVO Continues Run after Catheter News
Shares of Nuvelo Inc. (Nasdaq: NUVO) spiked up today after releasing its Phase III news earlier this morning. In early trading, NUVO was up 12 cents (7 percent) to $1.75 per share on volume of just over 372,000 shares. NUVO announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3) trial evaluating lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO). This open-label, single-arm trial will evaluate the safety and efficacy of a single 10 milligram dose of alfimeprase with a concentration of 5 milligrams per milliliter…